OR WAIT null SECS
December 06, 2024
Article
Pharmacokinetics and immunogenicity were also similar between reference tocilizumab and CT-P47.
December 03, 2024
CT-P41 had similar rates of bone mineral density increases and adverse events in data presented at the ACR 2024 Convergence.
November 06, 2024
If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.
November 02, 2024
The biosimilars month in review highlights new approvals, new safety findings, and new cost savings with biosimilars.
October 22, 2024
Ustekinumab-aekn is set to enter the US market no later than February 21, 2025, as per a settlement and license agreement between Janssen, Teva, and Alvotech.
October 14, 2024
Patients with IBD or arthritis were not found to be at a significantly higher risk of serious infection with a biosimilar versus originator of the common drugs.
The ustekinumab biosimilar will be available in early 2025, with indications to treat psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
October 09, 2024
BSC and Fresnius Kabi reached a deal facilitated by Evio Pharmacy Solutions by sidestepping pharmacy benefit managers.
October 08, 2024
The biosimilars month in review highlights a new approval and 2023 cost savings
October 01, 2024
The approval marks the fourth biosimilar approved for ustekinumab, for all approved indications.
